ClinicalTrials.gg
CompletedNCT03349723Updated Apr 11, 2022Results posted

This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men

A Phase 1 interventional study of BI 1265162 and Placebo in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The primary objective of this trial is to investigate the safety and tolerability of BI 1265162 in healthy male subjects following inhalative administration of single rising doses.

Secondary objective is the exploration of the pharmacokinetics (PK) of BI 1265162 after single dosing.

Read the detailed description

To investigate safety, tolerability and pharmacokinetics of BI 1265162 in man.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 50 years (incl.)
  • (BMI) of 18.5 to 29.9 kg/m2 (incl.)
  • (FEV1) and Forced Vital Capacity (FVC) of equal or greater than 80% of predicted normal, at screening and prior to randomisation
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, Pulse rate (PR) or (ECG)) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to the trial medication or its )
  • Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. /QTc interval prolongation)
  • Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on specified trial days
  • Alcohol abuse (consumption of more 30 g per day for males)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms in males) or any other relevant ECG finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • A history of chronic kidney disease (EGFR \<59 mls/min including corrections as per ethnicity)
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
  • The subject has a diagnosis history of pulmonary hyperreactivity
  • Male subjects with woman of child bearing potential () partner who are unwilling to use male (condom or sexual abstinence) from the first administration of trial medication until 14 days after last administration of trial medication (BI 1265162 or placebo)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    BI 1265162

    BI 1265162

    Drug: BI 1265162

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Single rising dose groups

  • DrugPlacebo

    Single rising dose groups

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Drug-related Adverse Events (AEs)

    Percentage of participants with drug-related adverse events (AEs).

    Time frame: From drug administration until end of trial examination, up to 9 days

Secondary outcomes

  1. Maximum Measured Concentration of BI 1265162 in Plasma (Cmax)

    Maximum measured concentration of BI 1265162 in plasma (Cmax).

    Time frame: Pharmacokinetic samples were taken pre-dose and 0:02 (hour: minute), 0:05, 0:10, 0:15, 0:20 , 0:30, 0:45, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 48:00 and 72:00 (Last time point only taken for 1200 µg) after drug administration

  2. Area Under the Concentration-time Curve of the BI 1265162 in Plasma Over the Time Interval 0 to 1 Hour Post-dose (AUC0-1)

    Area under the concentration-time curve of the BI 1265162 in plasma over the time interval 0 to 1 hour post-dose (AUC0-1)

    Time frame: Pharmacokinetic samples were taken pre-dose and 0:02 (hour: minute), 0:05, 0:10, 0:15, 0:20 , 0:30, 0:45, 1:00 after drug administration

07

Results

Posted Feb 23, 2022

Participant flow

This was single-blind, partially randomised, and placebo controlled within parallel dose groups trial. A total of 57 participants were entered and 56 were treated. The dose range for Treatment A to Treatment G was 3 μg to 1200 μg.

Participant flow — Overall Study
Milestone3 Microgram BI 126516210 Microgram BI 126516230 Microgram BI 1265162100 Microgram BI 1265162300 Microgram BI 1265162600 Microgram BI 12651621200 Microgram BI 1265162Placebo Matching BI 1265162
Started666666614
Completed666666614
Not completed00000000

Outcome measures

PrimaryPercentage of Participants With Drug-related Adverse Events (AEs)

Percentage of participants with drug-related adverse events (AEs).

Time frame:
From drug administration until end of trial examination, up to 9 days
Reported as:
Number · Percentage of participants (%)
Percentage of Participants With Drug-related Adverse Events (AEs)
Percentage of participants (%)3 Microgram BI 126516210 Microgram BI 126516230 Microgram BI 1265162100 Microgram BI 1265162300 Microgram BI 1265162600 Microgram BI 12651621200 Microgram BI 1265162Placebo Matching BI 1265162
Percentage of Participants With Drug-related Adverse Events (AEs)00016.716.7000
SecondaryMaximum Measured Concentration of BI 1265162 in Plasma (Cmax)

Maximum measured concentration of BI 1265162 in plasma (Cmax).

Time frame:
Pharmacokinetic samples were taken pre-dose and 0:02 (hour: minute), 0:05, 0:10, 0:15, 0:20 , 0:30, 0:45, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 48:00 and 72:00 (Last time point only taken for 1200 µg) after drug administration
Reported as:
Geometric mean · Picomoles Per Litre (pmol/L)
Maximum Measured Concentration of BI 1265162 in Plasma (Cmax)
Picomoles Per Litre (pmol/L)3 Microgram BI 126516210 Microgram BI 126516230 Microgram BI 1265162100 Microgram BI 1265162300 Microgram BI 1265162600 Microgram BI 12651621200 Microgram BI 1265162
Maximum Measured Concentration of BI 1265162 in Plasma (Cmax)17.8 ± 32.950.1 ± 46.6129.0 ± 40.1462.0 ± 53.21090.0 ± 26.03130.0 ± 30.66500.0 ± 73.1
Statistical analysis
  • 3 Microgram BI 1265162 vs 10 Microgram BI 1265162 vs 30 Microgram BI 1265162 vs 100 Microgram BI 1265162 vs 300 Microgram BI 1265162 vs 600 Microgram BI 1265162 vs 1200 Microgram BI 1265162 · Slope: 0.9806 · 95% CI 0.9155 to 1.0457Based on the estimate for the slope parameter (β), a 2-sided 95% CI for the slope was computed. Perfect dose proportionality would correspond to a slope of 1.
SecondaryArea Under the Concentration-time Curve of the BI 1265162 in Plasma Over the Time Interval 0 to 1 Hour Post-dose (AUC0-1)

Area under the concentration-time curve of the BI 1265162 in plasma over the time interval 0 to 1 hour post-dose (AUC0-1)

Time frame:
Pharmacokinetic samples were taken pre-dose and 0:02 (hour: minute), 0:05, 0:10, 0:15, 0:20 , 0:30, 0:45, 1:00 after drug administration
Reported as:
Geometric mean · Picomoles*Hour Per Litre (pmol*h/L)
Area Under the Concentration-time Curve of the BI 1265162 in Plasma Over the Time Interval 0 to 1 Hour Post-dose (AUC0-1)
Picomoles*Hour Per Litre (pmol*h/L)3 Microgram BI 126516210 Microgram BI 126516230 Microgram BI 1265162100 Microgram BI 1265162300 Microgram BI 1265162600 Microgram BI 12651621200 Microgram BI 1265162
Area Under the Concentration-time Curve of the BI 1265162 in Plasma Over the Time Interval 0 to 1 Hour Post-dose (AUC0-1)10.4 ± 42.428.7 ± 49.073.7 ± 43.4299.0 ± 45.2706.0 ± 25.91700.0 ± 34.53920.0 ± 76.4
Statistical analysis
  • 3 Microgram BI 1265162 vs 10 Microgram BI 1265162 vs 30 Microgram BI 1265162 vs 100 Microgram BI 1265162 vs 300 Microgram BI 1265162 vs 600 Microgram BI 1265162 vs 1200 Microgram BI 1265162 · Slope: 0.9892 · 95% CI 0.9207 to 1.0577Based on the estimate for the slope parameter (β), a 2-sided 95% CI for the slope was computed. Perfect dose proportionality would correspond to a slope of 1.

Adverse events

Collected over From drug administration until end of trial examination, up to 9 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3 Microgram BI 12651620/6 (0%)0/6 (0%)1/6 (16.7%)
10 Microgram BI 12651620/6 (0%)0/6 (0%)0/6 (0%)
30 Microgram BI 12651620/6 (0%)0/6 (0%)1/6 (16.7%)
100 Microgram BI 12651620/6 (0%)0/6 (0%)1/6 (16.7%)
300 Microgram BI 12651620/6 (0%)0/6 (0%)2/6 (33.3%)
600 Microgram BI 12651620/6 (0%)0/6 (0%)0/6 (0%)
1200 Microgram BI 12651620/6 (0%)0/6 (0%)1/6 (16.7%)
Placebo Matching BI 12651620/14 (0%)0/14 (0%)2/14 (14.3%)
Most frequent other events
Most frequent other events
Event3 Microgram BI 126516210 Microgram BI 126516230 Microgram BI 1265162100 Microgram BI 1265162300 Microgram BI 1265162600 Microgram BI 12651621200 Microgram BI 1265162Placebo Matching BI 1265162
Dry eyeEye disorders0/60/60/60/61/60/60/60/14
NasopharyngitisInfections and infestations0/60/60/60/60/60/61/61/14
HeadacheNervous system disorders1/60/61/60/61/60/60/61/14
CoughRespiratory, thoracic and mediastinal disorders0/60/60/61/60/60/60/60/14

Baseline characteristics

Treated set(TS):This subject set included all subjects who had received at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(Years)3 Microgram BI 126516210 Microgram BI 126516230 Microgram BI 1265162100 Microgram BI 1265162300 Microgram BI 1265162600 Microgram BI 12651621200 Microgram BI 1265162Placebo Matching BI 1265162Total
Mean31.3 ± 3.631.8 ± 5.228.7 ± 4.744.7 ± 5.632.0 ± 7.334.5 ± 8.938.8 ± 9.835.1 ± 11.034.7 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)3 Microgram BI 126516210 Microgram BI 126516230 Microgram BI 1265162100 Microgram BI 1265162300 Microgram BI 1265162600 Microgram BI 12651621200 Microgram BI 1265162Placebo Matching BI 1265162Total
Female000000000
Male66666661456
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)3 Microgram BI 126516210 Microgram BI 126516230 Microgram BI 1265162100 Microgram BI 1265162300 Microgram BI 1265162600 Microgram BI 12651621200 Microgram BI 1265162Placebo Matching BI 1265162Total
Hispanic or Latino000000011
Not Hispanic or Latino66666661355
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)3 Microgram BI 126516210 Microgram BI 126516230 Microgram BI 1265162100 Microgram BI 1265162300 Microgram BI 1265162600 Microgram BI 12651621200 Microgram BI 1265162Placebo Matching BI 1265162Total
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American000000101
White66666651455
More than one race000000000
Unknown or Not Reported000000000
08

Study locations

1 site
  • CRS Clinical Research Services Mannheim GmbH
    Mannheim, 68167, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Mar 2018, 3 months.

Results were first posted in Feb 2022, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2017
First posted
Nov 21, 2017
StartActual
Nov 23, 2017
Primary completionActual
Mar 5, 2018
CompletionActual
Mar 5, 2018
Results first posted
Feb 23, 2022
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03349723
Responsible party
Sponsor
First posted
Nov 21, 2017
Start date
Nov 23, 2017
Primary completion
Mar 5, 2018
Completion
Mar 5, 2018
Results posted
Feb 23, 2022
Last update
Apr 11, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI-1265162

Start the discussion